Related Experiment Videos
Phase II trial of fotemustine in patients with metastatic malignant melanoma
C I Falkson1, G Falkson, H C Falkson
1Department of Medical Oncology, University of Pretoria, South Africa.
Abstract:
Fotemustine is a novel chloroethylnitrosourea, that readily penetrates the blood brain barrier. Preliminary French studies reported encouraging results with fotemustine in patients with cerebral metastases of malignant melanoma. Thirty-one patients with histologically confirmed metastatic malignant melanoma were entered on a phase II trial. The treatment regimen consisted of fotemustine, administered intravenously as a rapid infusion, at a dose of 100 mg/m2 on day 1, 8 and 15 every 4 to 5 weeks. Objective response (CR + PR) was documented in 3 patients. Median time to treatment failure (TTF) was 44 days and median survival was 164 days. Life threatening toxicity did not occur; hematological toxicity and nausea and vomiting were the most common toxicities. Despite a somewhat disappointing response rate, objective responses were documented in patients with cerebral metastases. Since no other chemotherapeutic agent has shown therapeutic efficacy in cerebral metastases from malignant melanoma fotemustine therefore warrants further study.
Insights
Fotemustine, a novel chemotherapy, shows potential in treating brain metastases from malignant melanoma. While response rates were modest, it warrants further investigation for this difficult-to-treat cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Malignant melanoma frequently metastasizes to the brain.
- Effective treatments for cerebral metastases are limited.
- Fotemustine is a novel chloroethylnitrosourea with blood-brain barrier penetration.
Purpose of the Study:
- To evaluate the efficacy and toxicity of fotemustine in patients with metastatic malignant melanoma.
- To assess fotemustine's activity against cerebral metastases.
Main Methods:
- A phase II trial involving 31 patients with metastatic malignant melanoma.
- Intravenous fotemustine at 100 mg/m2 on days 1, 8, and 15 every 4-5 weeks.
- Objective response, time to treatment failure, survival, and toxicity were assessed.
Main Results:
- Objective response (CR+PR) observed in 3 patients.
- Median time to treatment failure was 44 days; median survival was 164 days.
- Hematological toxicity, nausea, and vomiting were the most common adverse events; no life-threatening toxicities occurred.
Conclusions:
- Fotemustine demonstrated objective responses in patients with cerebral melanoma metastases.
- Despite a low overall response rate, fotemustine warrants further study due to its activity in brain metastases.
- Fotemustine represents a potential therapeutic option for malignant melanoma with brain involvement.